---
title: "Lakefront Biotherapeutics director Paulo Fontoura steps down after taking Sanofi R&D chief role"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292525783.md"
description: "Lakefront Biotherapeutics announced that board member Paulo Fontoura has resigned from his position. This departure follows his appointment as Executive Vice President and Global Head of R&D Pharma at Sanofi. The company stated it expects to name a successor to fill the resulting board vacancy."
datetime: "2026-07-13T20:01:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292525783.md)
  - [en](https://longbridge.com/en/news/292525783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292525783.md)
---

# Lakefront Biotherapeutics director Paulo Fontoura steps down after taking Sanofi R&D chief role

-   Lakefront Biotherapeutics said board member Paulo Fontoura resigned following his appointment as executive vice president, global head of R&D Pharma at Sanofi. \* The company expects to name a successor to fill the board vacancy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131601OMX\_\_\_**EUPR**NL\_GNW1001212586\_nl) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Lakefront Biotherapeutics Buys Back 97,497 Shares Under Ongoing Repurchase Program](https://longbridge.com/en/news/294869610.md)
- [Sanofi asked to change Dupixent ads after Galderma challenge](https://longbridge.com/en/news/295117261.md)
- [Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D](https://longbridge.com/en/news/294405008.md)
- [Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates](https://longbridge.com/en/news/294956717.md)
- [Lakefront Biotherapeutics H1 FY26 net sales drop 87% to EUR 18.6 million; operating loss narrows 54% to EUR 107.2 million](https://longbridge.com/en/news/295443360.md)